Generated September 8, 2026 at 8:30 PM ET
· Covers September 8 trading day
· 9 of 251 ready 8-Ks selected
· AI-assisted overview
Several notable corporate actions and disclosures marked the day. GE Aerospace announced a $11.75B acquisition of Consolidated Precision Products, while AEVEX closed a $600M deal for BlackSea Technologies, and Sangamo completed a $50M asset sale to Eli Lilly amid Chapter 11 proceedings. Intellia Therapeutics received FDA Priority Review for its in vivo CRISPR therapy, while Estrella Immunopharma and Aterian disclosed Nasdaq compliance issues. Boston Scientific warned of a material cyber incident impact on results, and Veradigm reported a vendor data breach. Structure Therapeutics released positive clinical data for its obesity and cardiometabolic programs.
SGMO
SANGAMO THERAPEUTICS, INC
M&A
negative
materiality 0.85
September 8, 2026, 4:06 PM ET
Sangamo completes $50M asset sale to Eli Lilly, files July Chapter 11 operating report
- Completed $50M asset sale to Eli Lilly on 9/4/26; includes STAC-BBB capsid, zinc finger, modular integrase platforms, and prion program ST-506.
- July 2026 MOR: cash $16.9M, assets $155.1M, liabilities $97.1M; pre-petition unsecured debt $78.1M, post-petition debt $19.0M.
- July operating report: net loss $11.2M for month, cumulative loss $14.9M; G&A $3.8M, reorganization items $4.2M.
M&A
positive
materiality 0.90
September 8, 2026, 7:46 AM ET
GE Aerospace to acquire Consolidated Precision Products for $11.75B
- Purchase price $11.75B; financed with $7B cash plus new debt; expected close H2 2027.
- CPP valued at ~18x 2027 EBITDA including net synergies, ~26x without; ~$200M net synergies.
- Deal accretive to adjusted EPS and free cash flow in year 1 (excl. one-time costs and deal amortization).
M&A
positive
materiality 0.85
September 8, 2026, 4:43 PM ET
AEVEX closes $600M acquisition of BlackSea Technologies, adds maritime unmanned systems
- Total enterprise value $600M; paid in $350M stock (12.7M shares) plus cash, with $5M escrow adjustment.
- Up to $50M contingent consideration if AVEX hits $28 VWAP and BlackSea meets revenue/gross profit targets.
- BlackSea becomes AEVEX Maritime Systems division led by Bob Pudney; 350+ USVs delivered, 25,000+ operational hours.
ESLA
Estrella Immunopharma, Inc.
regulatory
negative
materiality 0.80
September 8, 2026, 5:25 PM ET
Estrella Immunopharma receives Nasdaq delisting notice for MVLS below $35M
- Nasdaq letter Sept 1, 2026: MVLS below $35M for 30 straight business days (Jul 21-Aug 31, 2026).
- Also fails alternative standards: stockholders' equity <$2.5M, net income <$500k.
- Compliance period until Mar 1, 2027; must hit $35M MVLS for 10 consecutive days.
regulatory
negative
materiality 0.80
September 8, 2026, 4:25 PM ET
Aterian receives Nasdaq bid price deficiency notice; CFO terminated, CEO interim CFO
- Nasdaq notified Aterian of non-compliance with $1.00 min bid price rule; 180-day cure period until March 1, 2027.
- CFO Joshua Feldman terminated Sep 4, 2026 per transition agreement; receives severance benefits.
- CEO David E. Lazar named interim CFO while company searches for full-time replacement.
NTLA
Intellia Therapeutics, Inc.
regulatory
positive
materiality 0.80
September 8, 2026, 4:05 PM ET
Intellia's lonvo-z BLA accepted by FDA with Priority Review for HAE; PDUFA March 10, 2027
- FDA accepted BLA for lonvo-z (formerly NTLA-2002) for HAE with Priority Review; PDUFA target date March 10, 2027.
- No advisory committee currently planned; if approved, lonvo-z would be first in vivo CRISPR therapy and only one-time HAE treatment.
- Phase 3 HAELO (80 patients): 87% reduction in mean monthly attacks vs placebo (p<0.0001) during weeks 5-28.
BSX
BOSTON SCIENTIFIC CORP
cyber
negative
materiality 0.90
September 8, 2026, 6:15 AM ET
Boston Scientific cyber incident to materially hit Q3 and FY 2026 results; will miss guidance
- Incident detected Aug 25, 2026; no evidence of ongoing unauthorized access as of Sept 7, 2026.
- Major distribution centers processing/shipping orders at or above normal levels; sterilization facilities operational.
- Manufacturing resumed across most global facilities; full recovery timeline uncertain.
GPCR
Structure Therapeutics Inc.
other material
positive
materiality 0.90
September 8, 2026, 8:09 AM ET
Structure Therapeutics: ACCG-2671 SAD positive, aleniglipron 72-wk OLE up to 16.2% weight loss
- ACCG-2671 SAD: 31 healthy adults, ~6-day half-life, no SAEs, 3.3% mean weight loss at Day 24 (10 mg), CTX-1 down ~60%.
- Aleniglipron 72-wk OLE: 11.6%/14.4%/16.2% weight loss for 45/90/120 mg arms; >1/3 of 90/120 mg cohorts >20% loss (35.9/40.5 lbs).
- Placebo crossover with 2.5 mg start: 9.0% (22.7 lbs) at 36 wks; <5% discontinuation due to AEs; improved GI tolerability.
—
Veradigm Inc.
cyber
negative
materiality 0.55
September 8, 2026, 4:29 PM ET
Veradigm discloses vendor cyber incident exposing patient data including SSNs
- Third-party vendor cybersecurity incident: stolen credentials accessed Veradigm API, downloading patient personal data including some Social Security numbers.
- No clinical or medical data involved; access limited to that interface, not broader systems; no operational disruptions.
- Law enforcement notified; investigation ongoing; affected customers and individuals notified, credit monitoring offered where applicable.